<!DOCTYPE html>
<html class="no-js">

<head>
	<meta charset="utf-8">
	<meta http-equiv="X-UA-Compatible" content="IE=edge">
	<title>Cáncer Ginecológico</title>
	<meta name="viewport" content="width=device-width, initial-scale=1">
	<meta name="description" content="Cáncer Ginecológico" />
	<meta name="keywords" content="ginecologia, oncologia, medicina" />
	<meta name="author" content="e-oncologia" />

	<link rel="shortcut icon" type="image/png" href="images/logopeque.png" />

	<link href="https://fonts.googleapis.com/css?family=Open+Sans&display=swap" rel="stylesheet">
	<link href='https://fonts.googleapis.com/css?family=Montserrat:400,700' rel='stylesheet' type='text/css'>

	<link rel="stylesheet" href="css/animate.css">
	<link rel="stylesheet" href="css/icomoon.css">
	<link rel="stylesheet" href="css/bootstrap.css">
	<link rel="stylesheet" href="css/owl.carousel.min.css">
	<link rel="stylesheet" href="css/owl.theme.default.min.css">
	<link rel="stylesheet" href="css/style.css">
	<script src="js/modernizr-2.6.2.min.js"></script>

</head>

<body>

	<div id="ico-page">
		<a href="#" class="js-ico-nav-toggle ico-nav-toggle"><i></i></a>

		<aside id="ico-aside" role="complementary" class="border js-fullheight" style="background-image: url(images/BGoscuro.jpg);">
			<p><br></p>
			<h2 id="ico-logo"><a href="index.html"><img src="images/logo.png" height="80"></a></h2>
			<nav id="ico-main-menu" role="navigation">
				<ul>
					<li><a href="m1u0.html"><span class="bgdestacado2">PRESENTACIÓN</span></a></li>
					<br>
					<li><a href="m1u1.html"><span class="bgdestacado2">MÓDULO 1</span><br>CÁNCER DE CÉRVIX</a></li>
					<br>
					<li><a href="m2u1.html"><span class="bgdestacado2">MÓDULO 2</span><br>CÁNCER DE ENDOMETRIO</a></li>
					<br>
					<li><a href="m3u0.html"><span class="bgdestacado2">MÓDULO 3</span><br>CÁNCER DE OVARIO</a></li>
					<br>
					<li><a href="m4u0.html"><span class="bgdestacado2">MÓDULO 4</span><br>OTROS TUMORES GINECOLÓGICOS</a></li>
					<br>
					<li><a href="m5u1.html"><span class="bgdestacado2">BIBLIOGRAFÍA </a></li>
					<ol>
						<li><a href="#1">bibliografía del módulo 1</a></li>
						<li><a href="#2">bibliografía del módulo 2</a></li>
						<li><a href="#3">bibliografía del módulo 3</a></li>
						<li><a href="#4">bibliografía del módulo 4</a></li>
					</ol>
				</ul>
			</nav>
		</aside>


		<div id="ico-main">

			<div class="ico-cabecera">
				<div class="ico-narrow-content animate-box">
					<img src="images/ICONO.png" alt="" class="img-responsive centrada">
				</div>
			</div>



			<div class="ico-narrow-content">
				<div class="row animate-box" data-animate-effect="fadeInLeft">
					<div class="col-md-12">
						<br>
						<h1>Bibliografía</h1>
					</div>
				</div>
			</div>
			<div class="ico-narrow-content">
				<div class="row animate-box" data-animate-effect="fadeInLeft">
					<div class="col-md-12">
						<h3 id="1">Módulo 1</h3>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Bosch FX et al.</span> The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002; 55: 244-265.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Chan JK et al.</span> Impact of the human papilloma vaccine on cervical cancer. J Clin Oncol 2007; 25: 2975-2982.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Di Mario S et al.</span> Are the Two Human Papillomavirus Vaccines Really Similar? A Systematic Review of Available Evidence: Efficacy of the Two Vaccines against HPV. J Immunol Res 2015;2015:435141.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Angioli R et al.</span> Ten years of HPV vaccines: State of art and controversies. Crit Rev Oncol Hematol 2016;102:65-72.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Ayhan A et al.</span> A comparison of prognoses of FIGO stage IB adenocarcinoma and squamous cell carcinoma. Int J Gynecol Cancer 2004; 14: 279-285.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Baalbergen A et al.</span> Prognostic factors in adenocarcinoma of the uterine cervix. Gynecol Oncol 2004; 92: 262-267.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Bipat S et al.</span> Computed tomography and magnetic resonance imaging in staging of uterine cervical cancinoma: a systematic review. Gynecol Oncol 2003; 91: 59-66.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Bonomi P et al.</span> Randomized trial of three cisplatin dose schedules in squamous-cell carcinoma of the cervix: A Gynecologic Oncology Group Study. J Clin Oncol 1985; 3: 1079.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Brewer CA et al.</span> Cisplatin plus gemcitabine in previously treated squamous cell carcinoma of the cervix: A phase II study of the Gynecologic Oncology Group. Gynecol Oncol 2006; 100: 385-388.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Chen MF et al.</span> Clinical outcome in posthysterectomy cervical cancer patients treated with concurrent cisplatin and intensity-modulated pelvic radiotherapy: a comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys 2007; 67: 14438-1444.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Delgado G et al.</span> Prospective surgical-pathological study of disease free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1990; 38: 352-357.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Delgado G et al.</span> Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: A Gynecologic Oncology Group study. Gynecol Oncol 1990; 38: 352-357.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Dueñas-González A et al.</span> Phase III, open-label, randomized study comparing concurrent gemcitabine plus cisplatin and radiation followed by adjuvant gemcitabine and cisplatin versus concurrent cisplatin and radiation in patients with stage IIB to IVA carcinoma of the cervix. J Clin Oncol 2011;29(13):1678.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Eifel PJ et al.</span> Adenocarcinoma of the uterine cervix: prognosis and patterns of failure in 367 cases treated at the M.D. Anderson Cancer Center between 1965 and 1985. Cancer 1990; 65: 2507.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Eifel PJ et al.</span> The influence of tumor size and morphology on the outcome of patients with FIGO stage IB squamous cell carcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys 1994; 29: 9-16.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Franco EL et al.</span> Epidemiologic evidence and human papillomavirus infection as a necessary cause of cervical cancer. J Natl Cancer Inst 1999; 91: 506-511.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Frumovitz M et al.</span> Lymphatic mapping and sentinel lymph node detection in women with cervical cancer. Gynecol Oncol 2008; 110: S17-20.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Fuller AF JR et al.</span> Determinants of increased risk for recurrence in patients undergoing radical hysterectomy for stage IA and IIB carcinoma of the cervix. Gynecol Oncol 1989; 33: 34-39.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Future II Study Group.</span> Quadrivalent vaccine against HPV to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-1927.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Fyles AW et al.</span> Prognostic factors in patients with cervix cancer treated by radiation therapy: results of a multiple regression analysis. Radiother Oncol 1995; 35: 107-117.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Garland SM et al.</span> Quadrivalent vaccine against HPV to prevent anogenital disease. N Engl J  Med 2007; 356: 1928-1943.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Goncalves A et al.</span> A phase II trial to evaluate gefitinib as second or third line treatment in patients with recurring locoregionally advanced or metastatic cervical cancer. Gynecologic Oncology 2008; 108: 42-46.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Green J et al.</span> Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev 2005 (3): CD002225.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Green J et al.</span> Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet 2001; 358: 781-786.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Harper DM et al.</span> Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with HPV types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-1765.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Harper DM et al.</span> Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine againts HPV types 16 and 18: follow-up from a randomised control trial. Lancet 2006; 367: 147- 1255.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Holowaty P et al.</span> Natural History of displasia of the uterine cervix. J Natl Cancer Inst 1999; 91: 252-258.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Juretzka et al.</span> Detection of pelvic lymph node micrometastasis in stage IA2-IB2 cervical cancer by inmunohistochemical analysis. Gynecol Oncol 2004; 93: 107-11.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Kitagawa R et al.</span> Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Cisplatin in Metastatic or Recurrent Cervical Cancer: The Open-Label Randomized Phase III Trial JCOG0505. J Clin Oncol 2015;33:2129.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Kleine W et al.</span> Prognosis of the adenocarcinoma of the cervix uteri: a comparative study. Gynecol Oncol 1989; 35: 145-149.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Lanciano RM et al.</span> Randomized comparison of weekly cisplatin or protacted venous infusion of fluorouracil in combination with pelvic radiation in advanced cervical cancer: A Gynecologic Oncology Group study. J Clin Oncol 2005; 23: 8289-8295.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Landoni F et al.</span> Randomized study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997; 350: 535-540.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Long HL et al.</span> Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: A Gynecologic Oncology Group Study. J Clin Oncol 2005; 23: 4626-4633.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Look KY et al.</span> An analysis of cell type in patients of surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 1996; 63: 304-311.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Lukka H et al.</span> Concurrent cisplatin-based chemotherapy plus radiotherapy for cervical cancer. A meta-analysis. Clin Oncol 2002; 14(3): 203-212.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Marchiole P et al.</span> Clinical significance of lymphovascular space involvement and lymph node micrometastasis in early-stage cevical cancer: a retrospective case-control surgico-pathological study. Gynecol Oncol 2005; 97: 727-732.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">MelnikowJ et al.</span> Natural history of cervical squamous intreepithelial lesios: a meta-analysis. Obstet Gynecol 1998; 92: 727-735.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Monk BJ et al.</span> Phase II trial of bevacizumab in the treatment of persistent or recurrent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. J Clin Oncol 2009; 27: 1069-1074.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Monk BJ et al.</span> Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: A Gynecologic Oncology Group Study. J Clin Oncol 2009; 27: 4649-4655.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Monk BJ et al.</span> Quality of life outcomes from a randomized phase III trial of cisplatin with or without topotecan in advanced carcinoma of the cervix: A Gynecologic Oncology Group Study. J Clin Oncol 2005; 23: 4617-4625.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Monk BJ et al.</span> Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group trials. Gynecol Oncol 2007; 105: 427-433.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Moore DH et al.</span> Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent or persistent squamous cell carcinoma of the cervix: A Gynecologic Oncology Group Study. J Clin Oncol 2004; 22: 3113-3119.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Morris M et al.</span> Pelvic radiation with concurrent chemotherapy compared with pelvic and para- aortic radiation for high risk cervical cancer. N Engl J Med 1999; 340: 1137-1143.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Mundt AJ et al.</span> Intensity-modulated whole pelvic radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 2002; 52: 1330-1337.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Muñoz N et al.</span> HPV in the etiology of human cancer. Vaccine 2006; 24S3: 1-10.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Nag S et al.</span> The American Brachytherapy Society rcomendations for high-dose-rate brachytherapy for carcinoma of the cervix. Int J Radiat Oncol Biol Phys 2000; 48: 201-211.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Omura GA et al.</span> Randomized trial of cisplatin versus cisplatin plus mitolactol versus cisplatin plus ifosfamide in advanced squamous carcinoma of the cervix: A Gynecologic Oncology Group Study. J Clin Oncol 1997; 15: 165. Parkin DM et als. Global Cancer Statistics. CA Cancer J Clin 2005; 55: 74-108.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Perez CA et al.</span> Tumor size, irradiation dose, and long-term outcome of carcinoma of uterine cervix. Int J Radiat Oncol Biol Phys 1998; 41: 307-317.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Peters WA et al.</span> Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation theraphy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000; 18: 1606-1613.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Reesink-Peters N et al.</span> Preoperative serum scamous cell carcinoma antigen levels in clinical decision making for patients with early-stage cervical cancer. J Clin Oncol 2005; 23: 1455-1462.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Rogers L et al.</span> Radioterapia adyuvante y quimiorradiación después de la cirugía por cáncer de cuello de útero. Biblioteca Cochrane Plus 2009; 4: CD007583.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Rosa DD et al.</span> Quimioterapia adyuvante con platino para el cáncer de cuello uterino en estadios tempranos. Biblioteca Cochrane Plus 2009; 3: CD005345.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Rose PG et al.</span> Long-term follow-up of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hidroxyurea during pelvic irradiation for locally advanced cervical cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2007; 25(19): 2804-2810.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Rutledge TL et al.</span> A comparison of stages IB1 and IB2 cervical cancers treated with radical hysterectomy. Is size the real difference? Gynecol Oncol 2004; 95: 70-76.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Rydzewska L et al.</span> Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer. Cochrane Database Syst Rev 2012;12:CD007406.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Schilder RJ et al.</span> A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix. A Gynecologic Oncology Group Study. Int J Gynecol Cancer 2009; 19: 929-933.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Sedlis A et al.</span> A randomized trial of pelvic radiation therapy versus no further therapy in selected patients with stage IB carcinoma of the cervix after radical hysterectomy and pelvic lymphadenectomy: A Gynecologic Oncology Group Study. Gynecol Oncol 1999; 73: 177-183.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Sevin BU et al.</span> Surgically defined prognostic parameters in patients with early cervical carcinoma: A multivariate survival tree analysis. Cancer 1996; 78: 1438-1446.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Sherman M.</span> Baseline cytology, HPV testing, and risk for cervical neoplasia: a 10-year cohort analysis. J Natl Cancer Inst 2003; 95: 46-52.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Sironi S et al.</span> Lymph node metastasis in patients with clinical early-stage cervical cancer: detection with integrated FDG PET/TC. Radiology 2006; 238: 272-279.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Stehman FB et al.</span> Carcinoma of the cervix treated with irradiation therapy. A multi-variate analysis of prognostic variables in the Gynecology Oncology Group. Cancer 1991; 67: 2776- 2785.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Stehman FB et al.</span> Carcinoma of the cervix treated with radiation therapy. A multi-variate analysis of prognostic variables in the Gynecologic Oncology Group. Cancer 1991; 67: 2276- 2285.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Tavassoli FA, Devilee P (editors).</span> Pathology and genetics of tumours of the breast and female genitale organs. Lyon: International Agency for Research On Cancer. 2003.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Tewari KS et al.</span> Improved survival with bevacizumab in advanced cervical cancer. N Engl J Med 2014;370:734.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Thomas GM.</span> Improved treatment for cervical cancer concurrent chemotherapy and radiotherapy. N Engl J Med 1999; 340: 1198-1200.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Tierney J et al.</span> Neoadjuvant chemotherapy for locally advanced cervical cancer: a systematic review and meta-analysis of individual patient data from 21 randomized trials. Eur J Cancer 2003; 39: 2470-2486.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Vale C et al.</span> Chemoradiotherapy for Cervical Cancer Meta-Analysis Collaboration. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials. J Clin Oncol 2008; 26(35): 5802-5812.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Van de Putte G et al.</span> Risk grouping in stage IB squamous cell cervical cancer. Gynecol Oncol 2005; 99: 106-112.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Whitney CW et al.</span> Randomized comparison of fluorouracil plus cisplatin vs. hydroxyurea as an adjunct to radiation therapy in stage IIB-IIIA carcinoma of the cervix with negative paraaortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group Study. J Clin Oncol 1999; 17: 1339-1348.</p>
						<br>

						<h3 id="2">Módulo 2</h3>
						<p class="marcoOSCURO"><span class="bgrosaclaro">ASTEC study group, Kitchener H, Swart AM et al.</span> Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomized study. Lancet 2009; 373 (9658): 125-136.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">ASTEC/EN.5 Study Group, Blake P, Swart AM et al.</span> Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG EN.5 randomised trials): pooled trial results, systematic review and meta-analysis. Lancet 2009; 373: 137-146.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Blake P, Swart AM, Orton J et al.</span> Adjuvant external beam radiotherapy in the treatment of endometrial cancer (MRC ASTEC and NCIC CTG RN.5 randomised trials): pooled trial results, systematic review, and meta-analysis. Lancet 2009:373:137-46.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Bokhman JV.</span> Two pathogenic types of endometrial carcinoma. Gynecol Oncol 1983; 15: 10-17.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Chan JK, Kapp DS et al.</span> Role of complete lymphadenectomy in endometrioid uterine cancer. Lancet Oncol 2007; 8 (9): 831-841.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Colombo N, Creutzberg C, Amant F et al.</span> ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up. Ann Oncol 2016;27(1):16-41.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">de Boer SM1, Powell ME2, Mileshkin L et al.</span> Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an  international, open-label, multicentre, randomised, phase 3 trial. Lancet Oncol. 2018 Mar;19(3):295-309. doi: 10.1016/S1470-2045(18)30079-2. Epub 2018 Feb 12.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Decruze SB, Green JA.</span> Hormone therapy in advanced and recurrent endometrial cancer: a systematic review. Int J Gynecol Cancer 2007; 17:964.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Fisher B, Constantino JP, Redmon CH et al.</span> Endometrial cancer in Tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project B-14. J Natl Cancer Inst 1994; 86: 527-37.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Fleming GF, Brunetto VL, Cella D et al.</span> Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgastrin in advanced endometrial cancer: a Gynecologic Oncology Group. J Clin Oncol 2004; 22: 2159-2166.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Galaal K, Al Moundhri M, Bryant A et al.</span> Adjuvant chemotherapy for advanced endometrial cancer. Cochrane Database Syst Rev 2014:CD010681.</p>



						<p class="marcoOSCURO"><span class="bgrosaclaro">Kong A, Johnson N, Kitchener HC, Lawrie TA.</span> Adjuvant radiotherapy fos stage I endometrial cancer: an updated Cochrane systematic review and meta-analysis. J Natl Cancer Inst 2012;104:1625-34.</p>
						
						<p class="marcoOSCURO"><span class="bgrosaclaro">Maggi R, Lissoni A, Spina F et al.</span> Adjuvant chemotherapy vs radiotherapy in high-risk endometrial carcinoma: results of a randomised trial. Br J Cancer 2006;95:266-71.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Martin-Hirsh PL, Lilford RJ, Jarvis GJ.</span> Adjuvant progetagen therapy for the treatment of endometrial cancer: review and meta-analysis of published randomized controlled trials Eur. J Obstet and Gynecol 1996; 65 (2): 201-7.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Matei D, Filiaci VL, Randall M, Steinhoff M.</span> A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma. J Clin Oncol. 2017;35S.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Morrow C, Bundy B, Homesley H et al.</span> Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group study. Gynecol Oncol 1990; 36: 166.</p>

						
						<p class="marcoOSCURO"><span class="bgrosaclaro">Morrow CP, Bundy BN, Kurman RJ, Creasman WT, Heller P, Homesley HD, et al.</span> Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium. Gynecol Oncol 1991; 40 (1): 55-65.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Nout RA, Putter H, Jürgenliemk-Schlz IM et al.</span> Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: results of the randomized PORTEC -2 Trial J. Clin Oncol. 2008; 26.</p>
						
						
						<p class="marcoOSCURO"><span class="bgrosaclaro">Randall E, Filiaci VL, Cella D et al.</span> Phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Groupstudy. J Clin Oncol 2006; 24: 36-44.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Susumu N, Sagae S, Udagawa Y et al.</span> Randomized phase III trial of pelvic radiotherapy versus cisplatin-based combined chemotherapy in patients with intermediate- and high-risk endometrial cancer: a Japanese Gynecologic Oncology Group study. Gynecol Oncol 2008; 108:226-33.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Talhouk A1, McConechy MK2, Leung S3 et al.</span> Confirmation of ProMisE: A simple, genomics- based clinical classifier for endometrial cancer. Cancer. 2017 Mar 1;123(5):802-813. doi: 10.1002/cncr.30496. Epub 2017 Jan 6.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">The Cancer Genome Atlas Research Network, Kandoth C, Schultz N, Cherniack AD, et al.</span> Integrated genomic characterization of endometrial carcinoma. Nature 2013;497(7447):67-73.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Thigpen JT, Brandy MF, Homesley HD.</span> Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study. J Clin Oncol 2004; 22: 3902-908.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Vale CL, Tierney J, Bull SJ, Symonds PR.</span> Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. Cochrane Database Syst Rev 2012: CD003915.</p>




						<h3 id="3">Módulo 3</h3>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Aghajanian C et al.</span> OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012;30(17):2039-45.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Armstrog DK, Bundy B, Wenzel L et al.</span> Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 5; 354 (1): 34-43.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Bell J, Brady M, Lage JM et al.</span> A randomized phase III of three versus six cycles of carboplatin and paclitaxel as adjuvant treatment in early stage ovarian epithelial carcinoma - a gynecologic Oncology Group study. J clin Oncol 2003; 21: 4350-4355.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Bookman MA. For the Gynecologic Cancer Intergroup (GCIG) Through the Ginecology Oncology Group (GOG).</span> GOGO182-ICON-5: 5-arm phase III randomized trial of paclitaxel and Carboplatin vs Combinatin with gemcitabine, PEG-liposomal doxorubicin, or topotecan in patients with advanced stage epithelial ovarian or primary peritoneal carcinoma. Proceedings Am Soc Clin Oncol 2006; abstract 5002.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Burger RA et al.</span> Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011;365(26):2473-83.</p>

						
						<p class="marcoOSCURO"><span class="bgrosaclaro">Cancer Genome Atlas Research Network.</span> Integrated genomic analyses of ovarian carcinoma. Nature 2011;474:609-15.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Chéreau E et al.</span> Comparison of peritoneal carcinomatosis scoring methods in predicting resectability and prognosis in advanced ovarian cancer. Am J Obstet Gynecol 2010;202(2):178.e1-178.e10.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Chiva L et al.</span> What Should We Expect After a Complete Cytoreduction at the Time of Interval or Primary Debulking Surgery in Advanced Ovarian Cancer? Ann Surg Oncol 2016;23(5):1666- 73.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Coleman RL et al.</span> Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2017 Oct 28;390(10106):1949-1961.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">du Bois A et al.</span> Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d'Investigateurs Nationaux Pour les Etudes des Cancers de l'Ovaire (GINECO). Cancer 2009;115(6):1234-44.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">du Bois A, Luck HJ, Meier W et al.</span> A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer. J Natl Cancer Inst 2003; 95: 1320-1329.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Elit L, Oliver TK, Covens A et al.</span> Intraperitoneal Chemotherapy in the first line treatment of women with stage III epithelial Ovarian Cancer. A systematic review with metaanalyses. Cancer 2 2007; 109: 692-702.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">González-Martín AJ, Calvo E, Bover I et al.</span> Randomised phase II trial of carboplatin versus paclitaxel-carboplatin in platinum sensitive recurrent advanced ovarian carcinoma: a GEICO (Grupo Español de Investigación en Cáncer de Ovario) study. Ann Oncol 2005;16 (5): 749-755.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Harter P et al.</span> Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO. Int J Gynecol Cancer 2011;21(2):289-95.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">International Collaborative Ovarian Neoplasm (ICON1) and European Organisation for Research and Treatment of cancer Collaborators.</span> Adjuvant chemotherapy in ovarian neoplasm (EORTC-ACTION)1 International Collaborative Ovarian Neoplasm Trial 1 and adjuvant chemotherapy in Ovarian Neoplasm trial two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian cancer. J Natl Cancer Inst 2003; 95: 105-112.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">International Collaborative Ovarian Neoplasm (ICON1) collaborators.</span> International Collaborative Ovarian Neoplasm Trial 1: A randomized trial of adjuvant chemotherapy in women with early-stage ovarian cancer. J Natl Cancer Inst 2003; 95: 125-132.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Jaaback K.</span> Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev 2006(1):CD005340.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Katsumata N et al.</span> Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009;374(9698):1331-8.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Ledermann J et al.</span> Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer. N Engl J Med 2012;366(15):1382-92.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">McGuire WP Hoskins WJ, Brady MF, et al.</span> Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and IV ovarian cancer. N Eng J Med 1996; 334: 1-8.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Mirza MR et al.</span> Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer. N Engl J Med. 2016 Oct 7.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Moore K et al.</span> Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer. N Engl J Med. 2018 Oct 21. doi: 10.1056/NEJMoa1810858.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Ozols RF, Bundy BN, Greer BE et al.</span> Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2003; 21: 3194-3200.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Perren TJ et al.</span> A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011;365(26):2484-96.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Pfisterer J, Plante M, Vergote I et al.</span> Gemcitabine/carboplatin vs carboplatin in platinum sensitive recurrent ovarian cancer. Results of a Gynecologic Cancer Intergroup randomized phase III trial of the AGO OVAR, the NCIC CTG and the EORTC GCG. J Clin Oncol 2004; ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 14S (July 15 Supplement): 5005.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Piccart MJ Bertelsen K, James K, et al.</span> A randomized intergroup trial of the cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three- years results. J Natl Cancer Inst 2000; 92: 699-708.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Poveda AM et al.</span> Bevacizumab Combined With Weekly Paclitaxel, Pegylated Liposomal Doxorubicin, or Topotecan in Platinum-Resistant Recurrent Ovarian Cancer: Analysis by Chemotherapy Cohort of the Randomized Phase III AURELIA Trial. J Clin Oncol 2015;33(32):3836-8.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Poveda A et al.</span> Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301phase III randomized trial. Ann Oncol 2011;22(1):39-48.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Pujade-Lauraine E et al.</span> Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. J Clin Oncol 2014;32(13):1302-8.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Pujade-Lauraine E et al.</span> Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 2017 Sep;18(9):1274-1284.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Tan DS et al.</span> "BRCAness" syndrome in ovarian cancer: a case-control study describing the clinical features and outcome of patients with epithelial ovarian cancer associated with BRCA1 and BRCA2 mutations. J Clin Oncol. 2008 Dec 1;26(34):5530-6.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">The ICON and AGO Collaborators.</span> Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003; 361: 2099-106.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Tothill RW et al.</span> Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res. 2008 Aug 15;14(16):5198-208.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Trimbos JB, Vergote I, Bolis G et al.</span> Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European Organisation for Research and Treatment of Cancer. Adjuvant chemotherapy in ovarian cancer. J Natl Cancer Inst 2003; 95: 113-125.</p>
							
						<p class="marcoOSCURO"><span class="bgrosaclaro">Vasey PA, Jayson GC, Gordon A et al.</span> Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst. 2004; 96 (22): 1682-1691.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Vergote I, De Brabanter Jos, Fyles A et al.</span> Prognostic importance of degree of differentiation and cyst rupture in stage I invasive epithelial ovarian carcinoma. Lancet 2001; 357: 176-182.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Vergote I et al.</span> Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med. 2010 Sep 2;363(10):943-53.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Winter WE, III, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG et al.</span> Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2007;25(24):3621-7.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Winter WE, III, Maxwell GL, Tian C, Sundborg MJ, Rose GS, Rose PG et al.</span> Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study. J Clin Oncol 2008;26(1):83-9.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Winter-Roach BL, Kitchener H.</span> Systematic review of adjuvant therapy for early epithelial ovarian cancer. Int J Gynecol Cancer 2003; 13: 395-404.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Xu K et al.</span> Prognostic significance of BRCA mutations in ovarian cancer: an updated systematic review with meta-analysis. Oncotarget. 2016 Sep 28. doi: 10.18632/oncotarget.</p>

						<h3 id="4">Módulo 4</h3>
						<p class="marcoOSCURO">AJCC Cancer Staging Manual (2010). Seventh Edition. Springer.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Alifrangis C, Agarwal R, Short D et al.</span> EMA/CO for high-risk gestational trophoblastic neoplasia: good outcomes with induction low-dose etoposide-cisplatin and genetic analysis. J Clin Oncol. 2013 Jan 10;31(2):280-6. doi: 10.1200/JCO.2012.43.1817. Epub 2012 Dec 10.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Alkatout I, Schubert M, Garbrecht N et al.</span> Vulvar cancer: epidemiology, clinical presentation, and management options Int J Womens Health. 2015; 7: 305–313. Published online 2015 Mar 20. doi: [10.2147/IJWH.S68979].</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Ayhan A et al.</span> A comparison of prognoses of FIGO stage IB adenocarcinoma and squamous cell carcinoma. Int J Gynecol Cancer 2004; 14: 279-285.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Benedetti P, Bellati F, Plotti F et al.</span> Neoadjuvant chemotherapy followed by radical surgery in patients affected by vaginal carcinoma. Gynecol Oncol. 2008;111(2):307. Epub 2008 Aug 16.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Bornstein J, Bogliatto F, Haefner HK et al.</span> The 2015 International Society for the Study of Vulvovaginal Disease (ISSVD) Terminology of Vulvar Squamous Intraepithelial Lesions. J Low Genit Tract Dis. 2016 Jan;20(1):11-4.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Casali P G, Abecassis N, Bauer S et al.</span> Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, Volume 29, Issue Supplement_4, 1 October 2018, Pages iv51–iv67.</p>
						<p class="marcoOSCURO"><a href="http://www.fasgo.org.ar/archivos/consensos/CONSENSO_FASGO_ETG.pdf">Consenso Fasgo "Enfermedad Trofoblástica Gestacional"</a></p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Cormio G, Loizzi V, Gissi F et al.</span> Cisplatin and vinorelbine chemotherapy in recurrent vulvar carcinoma. Oncology. 2009;77(5):281-4. doi: 10.1159/000259259. Epub 2009 Nov 16.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Dall’Asta A, Gizzo S, Musarò A et al.</span> Uterine smooth muscle tumors of uncertain malignant potential (STUMP): pathology, follow-up and recurrence. Int J Clin Exp Pathol. 2014; 7(11): 8136–8142.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">FIGO Committee on Gynecologic Oncology.</span> Current FIGO staging for cancer of the vagina, fallopian tube, ovary, and gestational trophoblastic neoplasia. Int J Gynaecol Obstet. 2009 Apr;105(1):3-4.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Gill BS, Bernard ME, Lin JF et al.</span> Impact of adjuvant chemotherapy with radiation for node- positive vulvar cancer: A National Cancer Data Base (NCDB) analysis. Gynecol Oncol. 2015 Jun;137(3):365-72. Epub 2015 Apr 11.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Hensley ML, Ishill N, Soslow R et al.</span> Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: Results of a prospective study. Gynecol Oncol 2009; 112:563.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Hensley ML, Wathen K, Maki RG et al.</span> Adjuvant treatment of high-risk primary uterine leiomyosarcoma with gemcitabine/docetaxel (GT), followed by doxorubicin (D): Results of phase II multicenter trial SARC005 (abstract #10021). J Clin Oncol 2010; 28:15s.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Lian J, Dundas G, Carlone M et al.</span> Twenty-year review of radiotherapy for vaginal cancer: an institutional experience. Gynecol Oncol. 2008;111(2):298.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Miyamoto DT, Viswanathan AN.</span> Concurrent chemoradiation for vaginal cancer. PLoS One. 2013;8(6):e65048. Epub 2013 Jun 7.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Moore DH, Ali S, Koh WJ et al.</span> A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study. Gynecol Oncol. 2012 Mar;124(3):529-33. Epub 2011 Nov 9.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Newlands ES, Mulholland PJ, Holden L et al.</span> Etoposide and cisplatin/etoposide, methotrexate, and actinomycin D (EMA) chemotherapy for patients with high-risk gestational trophoblastic tumors refractory to EMA/cyclophosphamide and vincristine chemotherapy and patients presenting with metastatic placental site trophoblastic tumors. J Clin Oncol. 2000 Feb;18(4):854-9.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Ngan HY, Kohorn EI, Cole LA et al.</span> Trophoblastic disease. Int J Gynaecol Obstet. 2012 Oct;119 Suppl 2:S130-6. doi: 10.1016/S0020-7292(12)60026-5.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Orton A, Boothe D, Williams N et al.</span> Brachytherapy improves survival in primary vaginal cancer. Gynecol Oncol. 2016;141(3):501. Epub 2016 Apr 1.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Osborne RJ, Filiaci V, Schink JC et al.</span> Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study. J Clin Oncol. 2011 Mar 1;29(7):825-31. doi: 10.1200/JCO.2010.30.4386. Epub 2011 Jan 24.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Pecorelli S.</span> Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105(2):103.</p>

						<p class="marcoOSCURO"><span class="bgrosaclaro">Pink D, Lindner T, Mrozek A et al.</span> Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol Oncol 2006; 101:464.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">de Sanjosé S, Alemany L, Ordi J et al.</span> Worldwide human papillomavirus genotype attribution in over 2000 cases of intraepithelial and invasive lesions of the vulva. Eur J Cancer. 2013 Nov;49(16):3450-61. doi: 10.1016/j.ejca.2013.06.033. Epub 2013 Jul 22.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Seckl MJ, Sebire NJ, Berkowitz RS.</span> Gestational trophoblastic disease. Lancet. 2010 Aug 28;376(9742):717-29. doi: 10.1016/S0140-6736(10)60280-2. Epub 2010 Jul 29.</p>


						<p class="marcoOSCURO"><span class="bgrosaclaro">Santaballa A, García Y, Herrero A et al.</span> SEOM clinical guidelines in gestational trophoblastic disease (2017) Clin Transl Oncol. 2018; 20(1): 38–46. doi: 10.1007/s12094- 017-1793-0.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Seckl MJ, Sebire NJ, Fisher RA et al.</span> Gestational trophoblastic disease: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013 Oct;24 Suppl 6:vi39-50. doi: 10.1093/annonc/mdt345.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Shah JP, Bryant CS, Kumar S et al.</span> Lymphadenectomy and ovarian preservation in low- grade endometrial stromal sarcoma. Obstet Gynecol 2008; 112:1102.</p>
						<p class="marcoOSCURO"><span class="bgrosaclaro">Siegel RL, Miller KD, Jemal A.</span> Cancer statistics, 2018. CA Cancer J Clin. 2018 Jan;68(1):7-30. doi: 10.3322/caac.21442. Epub 2018 Jan 4.</p>

					</div>
				</div>
			</div>
			
			

			
		




	
		

			

		



		


		
		

			

			

			

		
					

		

		

		









			<div class="ico-cabecera">
				<div class="ico-narrow-content">
					<div class="pager">
						<br>
					</div>
				</div>
			</div>










		</div>
	</div>

	<!-- jQuery -->
	<script src="js/jquery.min.js"></script>
	<!-- jQuery Easing -->
	<script src="js/jquery.easing.1.3.js"></script>
	<!-- Bootstrap -->
	<script src="js/bootstrap.min.js"></script>
	<!-- Carousel -->
	<script src="js/owl.carousel.min.js"></script>
	<!-- Stellar -->
	<script src="js/jquery.stellar.min.js"></script>
	<!-- Waypoints -->
	<script src="js/jquery.waypoints.min.js"></script>
	<!-- Counters -->
	<script src="js/jquery.countTo.js"></script>
	<!-- MAIN JS -->
	<script src="js/main.js"></script>
	<!-- partial -->
	<script src='https://cdnjs.cloudflare.com/ajax/libs/vue/2.5.13/vue.min.js'></script>
	<script src="js/scriptdiagram.js"></script>

</body>

</html>
